- Home
- ASO vs IOVA Comparison
ASO vs IOVA Comparison
Compare ASO & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASO
- IOVA
- Stock Information
- Founded
- ASO 1938
- IOVA 2007
- Country
- ASO United States
- IOVA United States
- Employees
- ASO N/A
- IOVA N/A
- Industry
- ASO Recreational Games/Products/Toys
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ASO Consumer Discretionary
- IOVA Health Care
- Exchange
- ASO Nasdaq
- IOVA Nasdaq
- Market Cap
- ASO 3.4B
- IOVA 975.1M
- IPO Year
- ASO 2020
- IOVA N/A
- Fundamental
- Price
- ASO $46.58
- IOVA $2.22
- Analyst Decision
- ASO Buy
- IOVA Buy
- Analyst Count
- ASO 16
- IOVA 11
- Target Price
- ASO $58.06
- IOVA $11.90
- AVG Volume (30 Days)
- ASO 1.7M
- IOVA 9.5M
- Earning Date
- ASO 09-02-2025
- IOVA 11-06-2025
- Dividend Yield
- ASO 1.09%
- IOVA N/A
- EPS Growth
- ASO N/A
- IOVA N/A
- EPS
- ASO 5.32
- IOVA N/A
- Revenue
- ASO $5,971,497,000.00
- IOVA $241,525,000.00
- Revenue This Year
- ASO $3.77
- IOVA $67.40
- Revenue Next Year
- ASO $6.50
- IOVA $56.32
- P/E Ratio
- ASO $8.93
- IOVA N/A
- Revenue Growth
- ASO N/A
- IOVA 636.99
- 52 Week Low
- ASO $33.34
- IOVA $1.64
- 52 Week High
- ASO $64.62
- IOVA $12.51
- Technical
- Relative Strength Index (RSI)
- ASO 35.47
- IOVA 43.75
- Support Level
- ASO $45.55
- IOVA $2.27
- Resistance Level
- ASO $51.23
- IOVA $2.38
- Average True Range (ATR)
- ASO 1.79
- IOVA 0.14
- MACD
- ASO -0.59
- IOVA -0.01
- Stochastic Oscillator
- ASO 8.67
- IOVA 28.21
About ASO Academy Sports and Outdoors Inc.
Academy Sports and Outdoors Inc is engaged in the full-line sporting goods and outdoor recreation retailer in the United States. The company's product categories are outdoors, apparel, sports & recreation, and footwear.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.